Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies.

Autor: Abdul-Ghani T; Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA., Puckett C; Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA., Migahid O; Hamad General Hospital, Doha, Qatar., Abdelgani S; Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA., Migahed A; Hamad General Hospital, Doha, Qatar., Adams J; Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA., Triplitt C; Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA., DeFronzo R; Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA., Jayyousi A; Hamad General Hospital, Doha, Qatar., Abdul-Ghani M; Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Sep; Vol. 24 (9), pp. 1810-1818. Date of Electronic Publication: 2022 Jun 29.

Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study.

Autor: Abdul-Ghani M; Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.; Dasman Diabetes Institute, Kuwait City, Kuwait., Migahid O; Academic Health System, Hamad General Hospital, Doha, Qatar., Megahed A; Academic Health System, Hamad General Hospital, Doha, Qatar., DeFronzo RA; Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Al-Ozairi E; Dasman Diabetes Institute, Kuwait City, Kuwait., Jayyousi A; Academic Health System, Hamad General Hospital, Doha, Qatar.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Dec; Vol. 22 (12), pp. 2287-2294. Date of Electronic Publication: 2020 Sep 03.

Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.

Autor: Ponirakis G; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar.; Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK., Abdul-Ghani MA; National Diabetes Center, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.; Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas, USA., Jayyousi A; National Diabetes Center, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar., Zirie MA; National Diabetes Center, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar., Qazi M; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., Almuhannadi H; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., Petropoulos IN; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., Khan A; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., Gad H; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., Migahid O; National Diabetes Center, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.; Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas, USA., Megahed A; National Diabetes Center, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar., Al-Mohannadi S; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., AlMarri F; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., Al-Khayat F; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., Mahfoud Z; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar., Al Hamad H; Rumailah Hospital, Hamad Medical Corporation, Doha, Qatar., Ramadan M; Rumailah Hospital, Hamad Medical Corporation, Doha, Qatar., DeFronzo R; Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas, USA., Malik RA; Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar.; Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK.; National Diabetes Center, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.; Institute of Cardiovascular Science, University of Manchester, Manchester, UK.

Publikováno v: Journal of diabetes investigation [J Diabetes Investig] 2021 Sep; Vol. 12 (9), pp. 1642-1650. Date of Electronic Publication: 2021 May 03.

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.

Autor: Ponirakis G; Department of Medicine, Weill Cornell Medicine, Doha, Qatar.; Manchester Metropolitan University, Manchester, Greater Manchester, UK., Abdul-Ghani MA; Diabetes Division, University of Texas Health Science Center, San Antonio, Texas, USA., Jayyousi A; Department of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar., Almuhannadi H; Department of Medicine, Weill Cornell Medicine, Doha, Qatar., Petropoulos IN; Weill Cornell Medical College in Qatar, Doha, Qatar., Khan A; Department of Medicine, Weill Cornell Medicine, Doha, Qatar., Gad H; Department of Medicine, Weill Cornell Medicine, Doha, Qatar., Migahid O; Department of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar., Megahed A; Department of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar., DeFronzo R; University of Texas Health Science Center at Houston, Houston, Texas, USA., Mahfoud Z; Department of Medicine, Weill Cornell Medicine, Doha, Qatar., Hassan M; Department of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar., Al Hamad H; Department of Geriatrics and Long Term Care, Qatar Rehabilitation Institute, Doha, Qatar., Ramadan M; Department of Geriatrics and Long Term Care, Qatar Rehabilitation Institute, Doha, Qatar., Alam U; Aintree University Hospitals NHS Foundation Trust, Liverpool, Liverpool, UK., Malik RA; Division of Cardiovascular Sciences, University of Manchester, Manchester, UK ram2045@qatar-med.cornell.edu.

Publikováno v: BMJ open diabetes research & care [BMJ Open Diabetes Res Care] 2020 Jun; Vol. 8 (1).

Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.

Autor: Abdul-Ghani M; Academic Health System, Hamad General Hospital, Doha, Qatar.; Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, Texas., Migahid O; Academic Health System, Hamad General Hospital, Doha, Qatar., Megahed A; Academic Health System, Hamad General Hospital, Doha, Qatar., Singh R; Academic Health System, Hamad General Hospital, Doha, Qatar., Fawaz M; Academic Health System, Hamad General Hospital, Doha, Qatar., DeFronzo RA; Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, Texas., Jayyousi A; Academic Health System, Hamad General Hospital, Doha, Qatar.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Mar; Vol. 21 (3), pp. 705-709. Date of Electronic Publication: 2018 Oct 25.